Mercedes E Gonzalez

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 6

Top Topics

Atopic Dermatitis

Placebo Controlled

Top Venues

Paediatric drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Mercedes E Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A Levit, Randy Prescilla
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatric drugs 25 (1) (2022)